Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes

Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.:

Source: Neurology Read More